Genetic Testing Initiative


Dr. Alan Shuldiner discusses a new gene-testing initiative for cardiology patients at the University of Maryland Medical Center. As part of a new personalized medicine initiative, the medical center is offering genetic testing to help doctors determine which medication a patient should take after a stenting procedure in order to prevent blood clots that could lead to serious - and potentially fatal - heart attacks and strokes. Up to one-fourth of the U.S. population carries at least one abnormal copy of the CYP2C19 gene, and research has shown that as a result, these individuals do not metabolize the standard anti-clotting medication clopidogrel effectively. Dr. Shuldiner, director of the Program in Personalized and Genomic Medicine at the University of Maryland School of Medicine, is leading the new gene-testing initiative at the medical center. Only a small number of hospitals in the United States have programs to offer routine genetic testing as part of their clinical practice.

Related Information

Official News Release

Maryland Heart Center 

Pharmacogenomics Research Network - National Institute of General Medical Sciences